Back to Top Skip to main content

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

COVID-19 presents challenges to heart health, physical fitness

Article
2/1/2021
Four military personnel, wearing masks, running on a track

Because of COVID-19 shutdowns, the overall health of both military personnel and beneficiaries has taken a hit over the last year.

Recommended Content:

February Toolkit | Healthy Heart and Total Force Fitness | Preventing Heart Disease | Coronavirus | Total Force Fitness | Physical Fitness | Heart Health

DOD experts explain: The science behind the COVID-19 vaccines

Article
2/1/2021
Medical personnel in PPE, conducting lab tests

Six weeks after the first vaccines were approved for emergency use authorization in the U.S., there is much more to know about the vaccine products developed against COVID-19.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Religious support team deploys to help frontline healthcare workers

Article
1/28/2021
Two military personnel, wearing masks, standing against a wall

Military chaplains and religious affairs specialist deploy to support our military medical providers responding working on the frontlines in response to the COVID-19 pandemic

Recommended Content:

Spiritual Fitness | Total Force Fitness | Coronavirus

SAMHS starts next phase of vaccine rollout, expands to 75 and older

Article
1/28/2021
Medical personnel giving a vaccine to a soldier in her right arm

Vaccinations for eligible 1b military personnel will be coordinated by their military units.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit | COVID-19 Vaccine for Adults Age 75 and Older

DHA director visits San Antonio military units, JBSA vaccination sites

Article
1/26/2021
Three military personnel, wearing masks, talking with each other in a hospital hallway

Army Lt. Gen Ronald Place, DHA director, recently visited JBSA vaccination sites and several other military locations in the greater San Antonio region.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

DOD vaccinating personnel worldwide against COVID-19

Article
1/26/2021
Two soldiers, wearing masks: one is getting a vaccine in his left arm

One-month update of COVID-19 distribution and administration efforts to DOD personnel.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

MHS Transformation results continue during COVID-19

Article
1/21/2021
Military personnel in a supply room, reaching for the top shelf

The MTF transition has enabled the DHA and the Services to increase standardization, eliminate duplicative contracts, and realize cost efficiencies by beginning the management of an enterprise-wide program.

Recommended Content:

Coronavirus | MHS Transformation

DOD recommends adults 75 and older should seek COVID-19 vaccine

Article
1/19/2021
Nursing home members, wearing masks, wait in a line to get their COVID vaccine

This age recommendation differs slightly from that of the Centers for Disease Control and Prevention, which recommends vaccinations for those 65 and older.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine for Adults Age 75 and Older | COVID-19 Vaccine Toolkit

LTG Place Vaccine Roll-Out Video

Video
1/18/2021
DHA Seal

DHA Director LTG Ron Place talks about coronavirus vaccines, their safety and efficacy, and encourages everyone to do their own research to get vaccinated.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

COVID-19 hinders blood donations during National Blood Donor Month

Article
1/14/2021
Navy Capt. R. Wade Blizzard, commanding officer of U.S. Navy Support Facility Diego Garcia, donates blood for the Navy Medicine Readiness and Training Units Diego Garcia walking blood bank on Dec. 17, 2020. The walking blood bank is a list of eligible donors who can provide blood in case of emergency. (U.S. Navy photo by Navy Seaman Apprentice Stevin Atkins)

Life-saving blood is in high-demand by the Armed Services Blood Program, as the COVID-19 has negatively impacted donations.

Recommended Content:

Armed Services Blood Program | Public Health | Coronavirus | Holiday Observances

Partnerships, COVID-19 are catalysts for enterprise virtual health

Article
1/14/2021
Image of Mr. Adler with text: "Partnerships, COVID-19 are catalysts for enterprise virtual health."

Jamie Adler, the lead for the DHA’s Virtual Health Clinical Integration Office, discusses the future of virtual health (VH).

Recommended Content:

Coronavirus | Connected Health | COVID-19 Vaccine Toolkit

COVID presents new set of challenges for DOD environmental health

Article
1/12/2021
Group of Marines, snowshoeing through the snow

One of the most important factors to take into account when maintaining one’s overall fitness is physical environment.

Recommended Content:

Total Force Fitness in a Pandemic | Reintroducing Total Force Fitness | January Toolkit | Coronavirus | COVID-19 Vaccine Toolkit | Total Force Fitness

DOD Launches “My MilLife Guide” Text Message Program to Boost Wellness

Article
1/11/2021
The new My MilLife Guide program supports the wellness of the military community.

DoD has launched My MilLife Guide, a new program that sends text messages designed to help the military community boost overall wellness while navigating stresses related to COVID-19.

Recommended Content:

Coronavirus | Public Health | Total Force Fitness | Health Readiness

Navy corpsman provides multitude of support to hospital

Article
1/8/2021
Two military personnel, wearing masks, in a supply room looking at the shelves

“Thinking outside the box is what makes a great person, let alone a Sailor," Tie said.

Recommended Content:

Public Health | Coronavirus

MTF facilities, markets set to resume transition heading into 2021

Article
1/6/2021
A military nurse, wearing a mask, prepares a needle for a vaccination

Butler says transition on track.

Recommended Content:

MHS Transformation | Coronavirus
<< < ... 6 7 8 9 10  ... > >> 
Showing results 76 - 90 Page 6 of 29

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.